WO2016137235A9 - 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 - Google Patents
마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 Download PDFInfo
- Publication number
- WO2016137235A9 WO2016137235A9 PCT/KR2016/001828 KR2016001828W WO2016137235A9 WO 2016137235 A9 WO2016137235 A9 WO 2016137235A9 KR 2016001828 W KR2016001828 W KR 2016001828W WO 2016137235 A9 WO2016137235 A9 WO 2016137235A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- mirna
- mir
- seq
- rna
- Prior art date
Links
- 108091070501 miRNA Proteins 0.000 title claims abstract description 147
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 65
- 201000011510 cancer Diseases 0.000 title claims abstract description 45
- 239000004480 active ingredient Substances 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- 239000002679 microRNA Substances 0.000 claims abstract description 147
- 108091055411 miR-3670-1 stem-loop Proteins 0.000 claims abstract description 26
- 108091039169 miR-3670-2 stem-loop Proteins 0.000 claims abstract description 26
- 108091024959 miR-3670-3 stem-loop Proteins 0.000 claims abstract description 26
- 108091045722 miR-3670-4 stem-loop Proteins 0.000 claims abstract description 26
- 108091063295 miR-8078 stem-loop Proteins 0.000 claims abstract description 26
- 108091086868 miR-4477a stem-loop Proteins 0.000 claims abstract description 25
- 230000001939 inductive effect Effects 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 69
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 20
- 208000020816 lung neoplasm Diseases 0.000 claims description 19
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 18
- 201000005202 lung cancer Diseases 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 11
- 206010027476 Metastases Diseases 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 9
- 230000007246 mechanism Effects 0.000 claims description 7
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 238000003682 fluorination reaction Methods 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 238000006198 methoxylation reaction Methods 0.000 claims description 3
- 230000011987 methylation Effects 0.000 claims description 3
- 238000007069 methylation reaction Methods 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 108091007428 primary miRNA Proteins 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 4
- 206010010144 Completed suicide Diseases 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 210000005170 neoplastic cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 239000002246 antineoplastic agent Substances 0.000 abstract description 9
- 230000035755 proliferation Effects 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 31
- 108020004459 Small interfering RNA Proteins 0.000 description 29
- 230000000295 complement effect Effects 0.000 description 21
- 108700011259 MicroRNAs Proteins 0.000 description 14
- 108091029119 miR-34a stem-loop Proteins 0.000 description 14
- 238000012216 screening Methods 0.000 description 14
- 230000001093 anti-cancer Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- 101000702707 Homo sapiens Smad nuclear-interacting protein 1 Proteins 0.000 description 9
- 102100030914 Smad nuclear-interacting protein 1 Human genes 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 230000030833 cell death Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 108020005345 3' Untranslated Regions Proteins 0.000 description 7
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 7
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 7
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 7
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 7
- 108091036066 Three prime untranslated region Proteins 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 6
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 230000009368 gene silencing by RNA Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 108091007773 MIR100 Proteins 0.000 description 5
- 102000013814 Wnt Human genes 0.000 description 5
- 108050003627 Wnt Proteins 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 108091091360 miR-125b stem-loop Proteins 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 102100024581 Alpha-taxilin Human genes 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102100032917 E3 SUMO-protein ligase CBX4 Human genes 0.000 description 4
- 108050004787 GREB1 Proteins 0.000 description 4
- 102000016251 GREB1 Human genes 0.000 description 4
- 102100039788 GTPase NRas Human genes 0.000 description 4
- 101000779390 Homo sapiens A-kinase anchor protein 11 Proteins 0.000 description 4
- 101000797579 Homo sapiens E3 SUMO-protein ligase CBX4 Proteins 0.000 description 4
- 101000872865 Homo sapiens E3 ubiquitin-protein ligase HECTD3 Proteins 0.000 description 4
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 4
- 101001008953 Homo sapiens Kinesin-like protein KIF11 Proteins 0.000 description 4
- 101001089248 Homo sapiens Receptor-interacting serine/threonine-protein kinase 4 Proteins 0.000 description 4
- 102100027629 Kinesin-like protein KIF11 Human genes 0.000 description 4
- 102100033734 Receptor-interacting serine/threonine-protein kinase 4 Human genes 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000009711 regulatory function Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 102100033811 A-kinase anchor protein 11 Human genes 0.000 description 3
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 3
- 102000004091 Caspase-8 Human genes 0.000 description 3
- 108090000538 Caspase-8 Proteins 0.000 description 3
- 102100023768 Constitutive coactivator of PPAR-gamma-like protein 1 Human genes 0.000 description 3
- 102100031116 Disintegrin and metalloproteinase domain-containing protein 19 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000766332 Homo sapiens Tribbles homolog 1 Proteins 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 108091030071 RNAI Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
- 102100026387 Tribbles homolog 1 Human genes 0.000 description 3
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 3
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108091074487 miR-34 stem-loop Proteins 0.000 description 3
- 108091092493 miR-34-1 stem-loop Proteins 0.000 description 3
- 108091059780 miR-34-2 stem-loop Proteins 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- -1 ADMA19 Proteins 0.000 description 2
- 101710168463 Alpha-taxilin Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102100034678 E3 ubiquitin-protein ligase HECTD3 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100039820 Frizzled-4 Human genes 0.000 description 2
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 2
- 101000760787 Homo sapiens Alpha-taxilin Proteins 0.000 description 2
- 101001048826 Homo sapiens Constitutive coactivator of PPAR-gamma-like protein 1 Proteins 0.000 description 2
- 101000777464 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 19 Proteins 0.000 description 2
- 101000885581 Homo sapiens Frizzled-4 Proteins 0.000 description 2
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091030146 MiRBase Proteins 0.000 description 2
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 description 2
- 102000057613 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Human genes 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 230000007022 RNA scission Effects 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008436 biogenesis Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000004611 cancer cell death Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010011122 A Kinase Anchor Proteins Proteins 0.000 description 1
- 102000014022 A Kinase Anchor Proteins Human genes 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101150109761 CKAP5 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102100028624 Cytoskeleton-associated protein 5 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 101001008948 Dictyostelium discoideum Kinesin-related protein 13 Proteins 0.000 description 1
- 102000017944 Dishevelled Human genes 0.000 description 1
- 108050007016 Dishevelled Proteins 0.000 description 1
- 101710121160 Disintegrin and metalloproteinase domain-containing protein 19 Proteins 0.000 description 1
- 108091035710 E-box Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 101100220774 Homo sapiens CKAP5 gene Proteins 0.000 description 1
- 101000766864 Homo sapiens Cytoskeleton-associated protein 5 Proteins 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101000574648 Homo sapiens Retinoid-inducible serine carboxypeptidase Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 description 1
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 102000011781 Karyopherins Human genes 0.000 description 1
- 108010062228 Karyopherins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100022699 Lymphoid enhancer-binding factor 1 Human genes 0.000 description 1
- 108090001093 Lymphoid enhancer-binding factor 1 Proteins 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027465 Metastases to skin Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010068086 Polyubiquitin Proteins 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710092482 Protein kinase 4 Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102100025483 Retinoid-inducible serine carboxypeptidase Human genes 0.000 description 1
- 102100028029 SCL-interrupting locus protein Human genes 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101150044133 Stil gene Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 108010083176 Twist-Related Protein 2 Proteins 0.000 description 1
- 102100031720 Twist-related protein 2 Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101001091265 Xenopus laevis Kinesin-like protein KIF11-A Proteins 0.000 description 1
- 101001091264 Xenopus laevis Kinesin-like protein KIF11-B Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108091033783 miR-153 stem-loop Proteins 0.000 description 1
- 108091058694 miR-4765 stem-loop Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000036456 mitotic arrest Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000002743 tongue squamous cell carcinoma Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
Definitions
- the present invention relates to a pharmaceutical composition comprising a double stranded miRNA as an active ingredient and used as an anticancer agent. More specifically, the present invention comprises miR-3670, miR-4477a, miR-8078 as a pharmaceutically active ingredient, which is characterized by a method of effectively inhibiting the proliferation of cancer cells or inducing spontaneous killing of cancer cells.
- An anticancer pharmaceutical composition comprising an acceptable carrier.
- the anticancer agent used as a drug treatment is mainly used to synthesize a monomolecular substance in an organic or inorganic method, which is effective for the protein which disturbs the signaling system by overexpression of phosphate activator protein included in the signal transmission system. It was developed and used to inhibit the activity of protein by binding.
- Traditional drug therapies in this manner have a number of side effects, one of which is that the material used as a drug is an artificially derived, ex vivo derived material and aims at proteins that are already overexpressed at the point of action of anticancer substances.
- siRNA small interfering RNA
- RISC RNA Induced Silencing Complex
- RISCs function as RNA enzyme scissors, which cut messenger RNA (hereinafter referred to as mRNA) to inhibit the production of proteins from mRNA.
- the siRNA included in the RISC combines with the mRNA having a sequence complementary to the siRNA sequence to form a double stranded RNA, and the RISC acts as an RNA enzyme scissors to cut the target mRNA so that the mRNA no longer repeats the protein. Do not function as a template.
- siRNA-based anticancer therapies are evaluated as more advanced than the monomolecular anticancer agents in that they block mRNA prior to the protein production stage and utilize RNA and the intrinsic RISC system.
- microRNA microRNA
- miRNA miRNA
- a therapeutic agent a therapeutic agent
- miRNA a therapeutic agent
- miRNA a therapeutic agent
- Agostini, M. & Knight, RA miR-34 from bench to oncotarget 5, 872-81, 2014.
- Burnett, JC & Rossi, JJ RNA-based therapeutics current progress and future prospects.Chem Biol 19, 60-71, 2012., Dangwal, S. & Thum, T.
- miRNAs are RNAs consisting of between 16 and 27 nucleotides and are classified as protein non-coding RNAs (mRNA), which are translated into proteins (Carthew, RW & Sontheimer, EJ Origins and Mechanisms of miRNAs and siRNAs.Cell 136, 642-55, 2009., Mac Farlane, L.-A. & Murphy, PR MicroRNA: Biogenesis, Function and Role in Cancer.Current Genomics 11, 537-561, 2010., Bartel, DP MicroRNAs : target recognition and regulatory functions.Cell 136, 215-33, 2009.).
- miRNAs are recorded in the genomes of higher flora and fauna cells and are known to play a key role in regulating cell metabolism and function, including cell production, growth, differentiation and death. To date, about 2,000 miRNAs are known in the human genome, and many of them are still unknown.
- miRNAs are transcribed into RNA by RNA polymerase called Pol II from the genome, the initial length of which is invariably variable (Carthew, RW & Sontheimer, EJ Origins and Mechanisms of miRNAs and siRNAs. Cell 136, 642). -55, 2009., Brodersen, P. & Voinnet, O. Revisiting the principles of microRNA target recognition and mode of action.Nat Rev Mol Cell Biol 10, 141-148, 2009.). This is due to the diversity of locations in which miRNAs are contained in the genome, which is located in the intron, the non-involved part of the protein production of mRNA, and transcribed at the same time as mRNA production and inter-genic regions on the genome.
- RNA hair-pin structure consists of approximately 70-80 nucleotides.
- Pre-miR inside the cell nucleus is transferred from the nucleus to the cytoplasm by the exportin protein, etc., and is second-processed by another RNA cleavage enzyme (RNase) called Dicer in the cytoplasm and composed of 16-27 nucleotides.
- RNase RNA cleavage enzyme
- Double stranded mature miR mature microRNA, hereinafter described as miR without other modifiers.
- One strand of RNA of the double stranded miR is selectively selected to have activity by binding to RISC, the ribonucleoprotein complex, and binds to the target mRNA using the sequence of miR.
- mRNA can be divided into three parts based on the involvement of protein production.
- '-UTR Un-Translated Region
- miRs bind primarily to 3'-UTRs (Carthew, RW & Sontheimer, EJ Origins and Mechanisms of miRNAs and siRNAs. Cell 136, 642-55, 2009., Bartel, DP MicroRNAs: target recognition and regulatory functions. Cell 136, 215-33, 2009.).
- siRNAs bind primarily to mRNA, including sequences complementary to the siRNA total sequence, whereas miRNAs are located 2-8 nucleotides from the 5 'end of the miRNA.
- the size of the seed region sequences is mainly used for target mRNA recognition, so that the sequence of the entire miRNA does not have a complete complementary sequence with the target gene and does not affect miRNA activity even if it contains some non-complementary sequence. (Bartel, DP MicroRNAs: target recognition and regulatory functions. Cell 136, 215-33, 2009.).
- the seed portion has a sequence size of 6-8 nucleotides
- various types of mRNAs having a complementary sequence in the 3 ′ UTR.
- a single miRNA can control several mRNAs simultaneously.
- the properties of these miRNAs impose their function as efficient regulators that miRNAs are involved in controlling many aspects of cell physiology, ranging from cell division, growth, differentiation, and death.
- the function of miRNA as a regulator acts as an advantage in implementing an effective anticancer effect, since siRNA targets the inhibition of single gene expression, while miRNA can simultaneously inhibit the expression of multiple cancer-causing genes. .
- a large number of mRNAs contain a region where one or more miRNAs may bind to the 3 'UTR, and bioinformatics estimates that approximately 30% of all mRNAs are regulated by miRNAs in protein production. have.
- miRNAs act as key regulators in this signaling pathway is seen to play an important role in major diseases, including cancer (MacFarlane, L.-A. & Murphy, PR MicroRNA: Biogenesis, Function and Role). Current Genomics 11, 537-561. 2010., Malone, CD & Hannon, GJ Small RNAs as guardians of the genome.Cell 136, 656-68. 2009., Nicoloso, MS, Spizzo, R., Shimizu, M., Rossi, S. & Calin, GA MicroRNAs--the micro steering wheel of tumour metastases.Nat Rev Cancer 9, 293-302. 2009., Landi, D., Gemignani, F. & Landi, S.
- miRNAs as anticancer therapeutic agents based on the deep linkage of miRNAs in cancers, and for example, clinical trials to verify the ability of miRNAs named miR-34a to inhibit cancer cell proliferation and induce death.
- miR-34a Attempts have recently been made to use miRNAs as anticancer therapeutic agents based on the deep linkage of miRNAs in cancers, and for example, clinical trials to verify the ability of miRNAs named miR-34a to inhibit cancer cell proliferation and induce death.
- miRNA that is more effective than miR-34a's ability to inhibit cancer cell proliferation and cancer cell death in clinical trials, and thus, miR-3670, miR-4477a, and miR-8078 have excellent anticancer efficacy.
- the present invention has been completed by confirming that these miRNAs achieve anticancer effects by effectively blocking the expression of many genes known as cancer causing genes.
- Disclosure of Invention It is an object of the present invention to provide a pharmaceutical composition for treating cancer, which discovers miRNAs excellent in inhibiting cancer cell proliferation and induces cancer cell death and comprises them as an active ingredient.
- the present invention provides a pharmaceutical composition for treating cancer comprising at least one miRNA selected from the group consisting of miR-3670, miR-4477a, miR-8078 as an active ingredient.
- FIG. 1 is representative of miR-34a, miR-100, and miR-125b selected from the entire screening library to measure the activity of miRNA included in the screening library, and each mRNA 3 ′ known to be inhibited by their expression.
- UTR was inserted into the 3'UTR of the luciferase expression vector to confirm the protein expression inhibition by miR-34a, miR-100 and miR-125b.
- FIG. 2 is a screening library consisting of about 1700 miRNAs treated with NCI-H460 lung cancer cell line to quantify cell growth using Resazurin reagent and convert it to relative growth values.
- Figure 3 shows the selection of about 50 miRNAs showing excellent efficacy in NCI-H460 cell line and using the measured relative cancer cell growth inhibition ability by WST-1 reagent.
- Figure 4 shows the degree of cell death after injection of miR-34a, miR-3670, miR-8078, miR-4477a into the cell transfection method to measure the effect of cell death in lung cancer cell line labeled with FITC dye Stained with Annexin V and analyzed by flow cytometry.
- FIG. 5 is a transfection method of injecting each miRNA into a lung cancer cell line and incubating for two weeks on a soft agar to measure the colony formation ability of the lung cancer cell line under the influence of miRNA.
- FIG. 6 shows a target candidate group using targetscan, a miRNA target prediction software, and Z-score showing cell death ability when the content of cells is inhibited using siRNA targeting them.
- Figure 7 shows the qPCR analysis the extent of expression of the genes identified in Figure 6 is inhibited by miRNA.
- FIG. 8 shows the degree of inhibition of luciferase protein expression by miRNA by cloning 3 ′ UTR of genes identified in FIG. 6 into 3 ′ UTR of luciferase.
- miRNA excellent efficacy than miR-34a known to have an anticancer effect to find out the miRNA excellent efficacy than miR-34a known to have an anticancer effect, and to determine its anticancer effect.
- 1700 miRNA screening libraries were synthesized (Table 1), and treated with NCI-H460 (lung cancer cell line) to measure cancer cell growth inhibition, and the following base sequence, which is more effective than miR-34a, was used. Having miR-3670, miR-4477a, miR-8078 was excavated (Table 3), it was confirmed that their anticancer efficacy is excellent (Figs. 4 to 8).
- the present invention relates to a pharmaceutical composition for treating cancer comprising at least one miRNA selected from the group consisting of miR-3670, miR-4477a, miR-8078 as an active ingredient.
- the miR-3670 may be characterized in that it comprises a double stranded RNA consisting of the nucleotide sequence of SEQ ID NO: 35 and SEQ ID NO: 36 or SEQ ID NO: 67 as an active ingredient.
- miR-4477a may be characterized in that it comprises a double stranded RNA consisting of the nucleotide sequence of SEQ ID NO: 43 and SEQ ID NO: 44 or SEQ ID NO: 68 as an active ingredient.
- miR-8078 may be characterized in that it comprises a double stranded RNA consisting of the nucleotide sequence of SEQ ID NO: 65 and SEQ ID NO: 66 or SEQ ID NO: 69 as an active ingredient.
- the miR-3670 template strand of the present invention may be characterized by SEQ ID NO: 35.
- miRNAs that are ultimately active in vivo are single stranded, they must be supplied intracellularly in double stranded form with base sequences having similar base sizes to bind RISC.
- the antisense sequence that binds the sequence has a sequence complementary to the active sequence.
- Complementary sequences can have a perfect complementary sequence, or can use endogenous sequences.
- Each double-stranded sequence, or base located at 3 'of one strand may not have a base bond with a relative sequence, which may be referred to as 3' overhang.
- the perfect complementary sequence of miR-3670 may be characterized by SEQ ID NO: 36.
- endogenous complementary sequence of miR-3670 may be characterized by SEQ ID NO: 67.
- the seed region corresponding to the second to the eighth to eighth bases of the miRNA active sequence is a major factor of activity, which is a long double strand comprising the same when preparing double stranded RNA. It can also manufacture and use.
- the active sequences of miR-4477a and miR-8078 and complementary sequences for double stranding with them may be characterized as described below.
- These double strands can also comprise double strands, including 3 ′ overhangs, as described above, and can also be used to construct double strands of long sequences, including seed regions.
- the miRNA discovered through the library screen in the present invention was confirmed to generate anticancer efficacy by controlling genes commonly known to play a major role in the induction, production and growth of cancer. It is a characteristic of miRNA that one species of miRNA can control multiple mRNA expressions at the same time. This property has been confirmed in the present invention, and is useful for developing oligo-based anticancer drugs.
- MiR-3670 of the present invention simultaneously inhibits the expression of CBX4, NRAS, CASR, TXLNA, SNIP1, HNF1A, FZD4, TRIB1, ADMA19, CKAP5, miR-8078 inhibits the expression of GREB1, HECTD3, RIPK4, and miR- 4477a was confirmed to simultaneously suppress the expression of STIL, KIF11, AKAP11, and FAM120A (FIG. 6).
- Target genes inhibited by miRNA of the present invention are known to function as follows.
- CBX4 (polycomb chromobox 4) is involved in tumor angiogenesis and tumor metastasis promotion, and NRAS is known to play a major role in tumor growth and cell division (Orouji, E. et al. MAP Kinase pathway gene copy alterations in NRAS / BRAF wild-type advanced melanoma.Int J Cancer (2015); Zheng, C. et al.MicroRNA-195 functions as a tumor suppressor by inhibiting CBX4 in hepatocellular carcinoma.Oncol Rep 33, 1115-22 (2015); Jiao , HK et al.
- CASR is found to be overexpressed in tumors and is required for tumor metastasis, and TXLNA is known to be involved in tumor growth and metastasis.
- Clinical results have been shown to have low survival rates for patients with high expression rates (Mashidori, T., Shirataki).
- Increased alpha-taxilin protein expression is associated with the metastatic and invasive potential of renal cell cancer.Biomed Res 32, 103-10 (2011); Tennakoon, S., Aggarwal, A. & Kallay, E. The calcium-sensing receptor and the hallmarks of cancer.Biochim Biophys Acta (2015); Ohtomo, N. et al.Expression of alpha-taxilin in hepatocellular carcinoma correlates with growth activity and malignant potential of the tumor.Int J Oncol 37, 1417-23 (2010)).
- SNIP1 known as transcriptional coactivator, promotes the expression of cyclin D1, which is essential for cell growth and division. It is known that the anticancer prognosis of patients with high expression levels of SNIP1 is poor. It is also known to promote tumor growth by binding to c-Myc, which acts as a major regulator of cell proliferation (Li, Q. et al. SNIP1: a new activator of HSE signaling pathway.Mol Cell Biochem 362 , 1-6 (2012); Fujii, M. et al.
- SNIP1 is a candidate modifier of the transcriptional activity of c-Myc on E box-dependent target genes.Mol Cell 24, 771-83 (2006); Roche, KC , Rocha, S., Bracken, CP & Perkins, ND Regulation of ATR-dependent pathways by the FHA domain containing protein SNIP1.Oncogene 26, 4523-30 (2007); Jeon, HS et al.High expression of SNIP1 correlates with poor prognosis in non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.Lung Cancer 82, 24-30 (2013); Liang, X. et al. Hypoxia-inducible factor-1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma.Oral Oncol 47, 92-7 (2011))
- HNF1A and FZD4 are constituents of the Wnt signaling system that is deeply involved in tumor growth and survival. Wnt signaling systems have been intensively studied in tumor biology and their importance is widely known.
- TRIB1 is known to play a role in tumor cell growth, metastasis, and cell suicide inhibition, and is known to be a factor in regulating MAPK signaling, one of the major signaling pathways for tumor growth (Pecina-Slaus, N. et al. Wnt).
- signaling transcription factors TCF-1 and LEF-1 are upregulated in malignant astrocytic brain tumors.Histol Histopathol 29, 1557-64 (2014); Ueno, K.
- et al.Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD 4.Mol Cancer Ther 11, 244-53 (2012); Lin, ZY et al. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1.Int J Cancer 135, 541-50 (2014) Soubeyrand, S., Naing, T., Martinuk, A. & McPherson, R. ERK1 / 2 regulates hepatocyte Trib1 in response to mitochondrial dysfunction.Biochim Biophys Acta 1833, 3405-14 (2013)).
- ADAM19 is a protein distributed in the cell membrane and is known to play a variety of biological roles, including cell-to-cell contact and contact with the extracellular matrix. In tumor biology, it is known to be deeply involved in tumor growth and metastasis. .
- the CKAP5 gene which is known to play an important role in tumor survival through gene functional screens, has also been found through the present invention to be controlled by the miRNA, and GREB1 is associated with a hormone signaling system in tissues or tumors that respond to hormones. It is known that the gene is overexpressed in various types of tumors and promotes cell growth (Zhang, Q. et al. Role of microRNA-30c targeting ADAM 19 in colorectal cancer. PLoS One 10, e0120698 (2015); Shan, N.
- HECTD3 is an E3 ubiquitin ligase that inhibits tumor death by attaching polyubiquitin to caspase-8, which triggers cell suicide, inducing degradation of caspase-8.
- Stabilizing MALT1 protein is known to increase drug resistance to cisplatin anticancer drugs.
- RIPK4 is a receptor-reactor protein kinase 4 that has been reported to activate the Wnt signal transduction system while inducing the accumulation of beta-catenin, a cell growth signaling factor. Artificial removal of RIPK4 has been shown to inhibit tumor growth in tumor animal models (Li, Y. et al.
- the HECTD3 E3 ubiquitin ligase facilitates cancer cell survival by promoting K63-linked polyubiquitination of caspase-8. Cell Death Dis 4, e935 (2013); Li, Y. et al. The HECTD3 E3 ubiquitin ligase suppresses cisplatin-induced apoptosis via stabilizing MALT 1. Neoplasia 15, 39-48 (2013); Huang, X. et al. Phosphorylation of Dishevelled by protein kinase RIPK4 regulates Wnt signaling.Science 339, 1441-5 (2013)).
- STIL gene which is an essential factor in the transition from G2 phase to M phase during cell cycle circulation, is observed to have high expression rate in various types of carcinoma and is known to be necessary for tumor proliferation and survival.
- KIF11 has also been reported as one of the factors necessary for the growth and metastasis of tumor cells and is known to inhibit tumor growth by inhibiting KIF11 activity (Erez, A. et al. Sil overexpression in lung cancer characterizes tumors with increased mitotic Oncogene 23, 5371-7 (2004); Erez, A. et al. The SIL gene is essential for mitotic entry and survival of cancer cells.Cancer Res 67, 4022-7 (2007); Tang, Y., Orth , JD, Xie, T.
- AKAP11 which binds to protein kinase A (PKA) to increase PKA activity, simultaneously binds to GSK-3beta and promotes phosphorylation of GSK-3beta by PKA.
- PKA protein kinase A
- Phosphorylated GSK-3beta loses its activity, which is recognized as a signal to promote growth in cells and is one of the major mechanisms that cause tumor growth.
- Tumor cells are exposed to various stress conditions such as acidic conditions and oxygen deficiency conditions, and maintain the mechanism of inhibiting the death of tumor cells even under these protective conditions.
- RNA-binding protein FAM120A is known to activate kinases such as Src to increase cell inhibition and drug resistance (Logue, JS et al.
- AKAP220 protein organizes signaling elements that impact cell migration). J Biol Chem 286, 39269-81 (2011); Whiting, JL et al. Protein Kinase A Opposes the Phosphorylation-dependent Recruitment of Glycogen Synthase Kinase 3beta to A-kinase Anchoring Protein 220.J Biol Chem 290, 19445-57 ( Tanji, C. et al.
- A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3beta (GSK-3beta) and mediates protein kinase A-dependent inhibition of GSK-3beta.J Biol Chem 277, 36955-61 ( Tanaka, M. et al. A novel RNA-binding protein, Ossa / C9orf10, regulates activity of Src kinases to protect cells from oxidative stress-induced apoptosis.Mol Cell Biol 29, 402-13 (2009); Bartolome, RA et al. IL13 Receptor alpha2 Signaling Requires a Scaffold Protein, FAM120 A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis. Cancer Res 75, 2434-44 (2015)).
- the growth of the cells is reduced as in the case of using miR-3670, miR4477a, miR-8078 when the intracellular contents of the genes are reduced using the siRNA (FIG. 6), miR-3670, miR When -4477a and miR-8078 were delivered into lung cancer cells, all mRNA expressions of the genes were reduced as qPCR results (FIG. 7).
- the genes are direct targets of miR-3670, miR-4477a, miR-8078 as a luciferase result (Fig. 8). This fact means that miR-3670, miR-4477a, miR-8078 induce the death of tumor cells by simultaneously inhibiting the expression of several genes important for tumor cell growth and survival in a direct manner.
- the cancer is lung cancer, liver cancer, gastric cancer, colon cancer, pancreatic cancer, gallbladder and biliary tract cancer, breast cancer, leukemia, esophageal cancer, non-Hodgkin's lymphoma, thyroid cancer, cervical cancer, skin cancer and metastases to other organs therefrom And one or more cancers selected from the group consisting of metastatic cancers induced and tumor cell disease produced by promoting abnormal cell division.
- the miRNA sequence that can be used as an active ingredient of the pharmaceutical composition for treating cancer provided by the present invention may be a sequence derived from a human genome or a miRNA sequence obtained from another animal-derived genome without limiting the miRNA-derived genome to a human genome.
- miRNAs may be used in the form of various miRNA derivatives (miRNA mimics) that generate the biological equivalent efficacy of miRNA, and may use a modified miRNA including a miRNA sequence including the same seed region.
- miRNA mimics miRNA mimics
- the length of SEQ ID NO: 1 or SEQ ID NO: 2 can be shortened, and short derivatives consisting of 15 nucleotides in length can be used.
- the miRNA derivative for the miRNA may partially include a phosphorothiolate structure in which a phosphate backbone structure is substituted with another element such as sulfur, and DNA instead of RNA. It can be used in the form of whole or partial substitution with PNA (petide nucleic acids) and LNA (locked nucleic acid) molecules, and also in the form of replacing the 2 'hydroxyl group of the RNA sugar with various functional structures, Methylation, methoxylation, fluorination, and the like, but are not limited to such modifications.
- PNA peer nucleic acids
- LNA locked nucleic acid
- miRNA is not limited to the double-stranded RNA of the mature miRNA (mature miRNA) and the miRNA derivative derived therefrom, and may be used in the form of a miRNA precursor, and the miRNA precursor may also be described as the RNA phosphate skeleton structure described above. Partial or total substitution of the nucleic acid with DNA, PNA, LNA, and the like, and modification of the 2 ′ hydroxyl group of the molecule per RNA are possible.
- the miRNA can be used in the form of miRNA precursors or primary miRNAs (pri-miRNA), which can be synthesized by chemical methods or expressed by delivery to cells in the form of plasmids (plasmids).
- miRNA precursors or primary miRNAs pri-miRNA
- plasmids plasmids
- a method of delivering miRNAs to cells cultured in a culture dish may be performed using a mixture with cationic lipids, an electrical stimulation method, or a method using a virus. It is not.
- the pharmaceutical composition for treating cancer comprising the miRNA of the present invention as an active ingredient may further include a pharmaceutically acceptable carrier, and may be formulated together with an enclosure.
- the term "pharmaceutically acceptable carrier” refers to a carrier or diluent that does not irritate an organism and does not inhibit the biological activity and properties of the administered compound.
- Acceptable pharmaceutical carriers in compositions formulated as liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary.
- Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
- Cancer preventive or therapeutic composition comprising the miRNA of the present invention and a pharmaceutically acceptable carrier is applicable to any formulation comprising it as an active ingredient, it can be prepared in oral or parenteral formulations.
- Pharmaceutical formulations of the invention may be oral, rectal, nasal, topical (including the cheek and sublingual), subcutaneous, vaginal or parenteral (intramuscular, subcutaneous). And forms suitable for administration by inhalation or insufflation.
- Oral dosage forms containing the composition of the present invention as an active ingredient include, for example, tablets, troches, lozenges, water-soluble or oily suspensions, preparation powders or granules, emulsions, hard or soft capsules, syrups or elixirs. can do.
- lactose For formulation into tablets and capsules, lactose, saccharose, sorbitol, mannitol, starch, amylopectin, binders such as cellulose or gelatin, excipients such as dicalcium phosphate, disintegrants such as corn starch or sweet potato starch, stearic acid masne It may include a lubricating oil such as calcium, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax, and in the case of a capsule, it may further contain a liquid carrier such as fatty oil in addition to the above-mentioned materials.
- a lubricating oil such as calcium, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax
- a liquid carrier such as fatty oil in addition to the above-mentioned materials.
- Formulations for parenteral administration comprising the composition of the present invention as an active ingredient, for injection, such as subcutaneous injection, intravenous injection or intramuscular injection, a suppository injection method or aerosol for spraying by inhalation through the respiratory system It can be formulated as.
- the compositions of the present invention may be mixed in water with stabilizers or buffers to prepare solutions or suspensions, which may be formulated for unit administration of ampoules or vials.
- solutions or suspensions which may be formulated for unit administration of ampoules or vials.
- a rectal composition such as suppositories or enemas, including conventional suppository bases such as cocoa butter or other glycerides.
- a propellant or the like may be combined with the additives to disperse the dispersed dispersion or wet powder.
- miRNA synthesis of strand sequence 21 versions of human miRNA sequences provided by miRBase, miRBase (www.mirbase.org), based on the stem-loop structure, and over 1700 miRNA screening libraries were used as solid synthesis methods used for conventional oligo synthesis.
- MiRNA synthesis of strand sequence Each strand of the synthesized miRNA was purified by reverse phase separation using C18 resin. All synthesized miRNA strands were determined using MALDI-TOF mass spectrometry to determine and confirm the synthesis of the intended sequence. To prepare a double stranded miRNA, the corresponding complementary strand was heated at 95 ° C. for 2 minutes in the presence of salt and then cooled slowly to bind the double strand.
- miR-34a, miR-100, miR-125b were selectively selected from about 1700 miRNA screening libraries.
- the selected miRNAs were selected from a large number of studies conducted on the target mRNA type that controls the function and expression, and on the binding regions that bind to each mRNA 3′UTR.
- the 3 'UTR portion of Bcl2, mTOR, and Lin28b mRNAs, which are well known to be controlled by miR-34a, miR-100, and miR-125b, were replaced with 3' UTRs of the firefly luciferase vector. Vectors corresponding to each miRNA were constructed.
- HEK-293T cell lines using lipofectamine 2000 (Lipofectamine 2000, Invitrogen), an intracellular delivery reagent for each vector and miR control, or oligo miR-34a, miR-100, and miR-125b corresponding to each vector.
- lipofectamine 2000 Lipofectamine 2000, Invitrogen
- oligo miR-34a, miR-100, and miR-125b corresponding to each vector.
- Luciferase activity was measured using a Luminometer (Thermo scientific) to confirm the activity of the synthesized miRNA (FIG. 1).
- each miRNA in the miRNA library was prepared using RNAiMAX reagent (Invitrogen). Transfection was performed so that the final concentration was 100nM. Since each miRNA was transfected three times, three experimental 96-well plates were prepared for each plate of the miRNA library stored in the 96-well plate. After culturing for 24 hours under the same conditions as the cell culture conditions, the fluorescence value generated by adding Resazurin reagent (Promega) was measured using a fluorimeter (Fluoremeter, Tecan). In order to relatively evaluate the ability of each miRNA to inhibit cell proliferation, the average value and standard deviation of 96 values measured on a 96-well plate were obtained. (Z-score) was calculated by substituting the formula below.
- x i is the measurement of each well
- ⁇ is the average of all wells in the plate
- ⁇ is the standard deviation.
- the standard deviation fold z i of each well is an average value obtained from three replicate plates. Through this, 50 primary candidate miRNAs with z values smaller than -2 were selected (FIG. 2, Table 2).
- More than 50 miRNA candidate groups obtained in the primary screening were used for secondary screening with improved measurement accuracy.
- Experimental conditions were performed in the same manner as the primary screening conditions, except that WST-1 reagent (Roche) was used instead of lesazurin as a reagent for measuring cell proliferation ability. WST-1 was used because the signal strength can be measured more quantitatively than lesazurin. Measurement of cell inhibition capacity by each miRNA is shown in Figure 3 relative to the control group, miR-34a was also included as a positive control.
- the method used in the screening is a method of measuring relative inhibition of cell proliferation by measuring the number of cells in a quantitative sense.
- Mechanisms for inhibiting the proliferation of cells include a method of slowing down the division cycle rate of cells and a method of inducing cell suicide.
- the degree of cell suicide was analyzed using a flow cytometer (Fluorescence Activated Cell Sorter, FACS). To this end, the cells were dispensed into 6-well plates, the miRNAs were injected into the cells with RNAiMAX reagent, and the cells were cultured under the conditions described above for 48 hours.
- the characteristics as tumor cells can be measured by culturing tumor cells using soft agar.
- a support such as a petri dish is required for growth, whereas tumor cells have characteristics that grow in an environment without a physically rigid support such as a soft agar.
- These tumor specific properties were used to determine cell population capacity in soft agar.
- NCI-H460 lung cancer cell lines were treated with control miRNA, miR-34a, miR-8078, miR-3670, miR-4477a and miR-4765, respectively, and incubated for 24 hours. Incubated weekly. Cells were stained with crystal violet dye to determine the number of each population (FIG. 5). As a result, the cells treated with miR-8078 and miR-3670 hardly formed a colony, and the cell group treated with miR-4477a showed a colony forming ability of about 30% of the control group.
- Example 7 Measurement of cell proliferation inhibitory effect of target mRNA of miRNA
- the target mRNA whose protein expression is controlled by the miRNA has a sequence that is partially complementary to the sequence of the miRNA.
- miRNA is particularly important in the seed region (seed region) sequence, because it inhibits the expression of genes by binding to mRNA having a sequence complementary to the seed region sequence.
- the seed region sequence is relatively short, 8-9 bases, the mRNA targeted for miRNA is predicted using software.
- the target genes were selected by determining whether or not the growth of the cells was inhibited after reducing the intracellular content of the target genes predicted through software using siRNA.
- TargetScan was used as a target prediction software widely used in this field, and a total of 600 genes were used as predicted targets of miR-3670, miR-4477a, and miR-8078. Selected. Three siRNAs were synthesized for each of the selected genes, and experiments were carried out in the same manner as in Example 3 using the siRNAs. The cells were dispensed into 96 well-plates, treated with each siRNA, incubated for 48 hours, and then the cell proliferation capacity was measured using the resazurin reagent. In the same manner as in Example 3, Z-score of each gene was calculated from the average of measured values of about 1800 (600 genes x 3 siRNAs) in total, and is shown in FIG. 6.
- the mode of action of miRNAs slows down the production of proteins from mRNA, and at the same time induces degradation of most of the targeted mRNAs. Therefore, by injecting miRNA into the cell and analyzing the content of the mRNA targeted by the miRNA using qPCR, it can be used as a criterion to determine whether the target mRNA of the miRNA by measuring the decrease in content.
- miR-3670, miR-4477a, and miR-8078 are injected into lung cancer cell lines, respectively. After 48 hours of incubation, RNA was extracted from each cell to quantitatively measure RNA content (FIG. 7). As a result, it was confirmed that the contents of expected target mRNAs of miR-3670, miR-4477a, and miR-8078 were significantly decreased.
- luciferase assay is commonly used as a method of directly measuring the relationship between miRNA and target mRNA.
- TargetScan software provides a 3 'UTR sequence containing a miRNA binding sequence, which is described in Example 2 above, and the gene cloning technique in the 3' UTR of the firefly luciferase. And the vector produced in this manner was transfected into Human Embryonic Kidney (HEK) cells simultaneously with the miRNA to measure the amount of luciferase expression of the vector.
- HEK Human Embryonic Kidney
- the renilla luciferase was also transfected at the same time to correct the measured value.
- miRNA, Firefly luciferase, Renilla luciferase were injected at the same time and incubated for 48 hours, and measured by luminometer (Luminometer) (FIG. 9). As a result, it was confirmed that each target mRNA is directly controlled by the miRNA.
- the pharmaceutical composition for treating cancer according to the present invention comprises one or more miRNAs selected from the group consisting of miR-3670, miR-4477a, miR-8078, as an active ingredient, and is used for clinical trials to measure suitability as an existing anticancer agent. It can be widely used as an anticancer treatment composition as it shows an improved anticancer effect as compared to the pharmaceutical composition for cancer treatment using active miR-34a and other miRNA as an active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
- miR-3670, miR-4477a, miR-8078로 구성된 군에서 선택되는 하나 이상의 miRNA를 유효 성분으로 포함하는 암 치료용 약학 조성물.
- 제1항에 있어서,상기 miR-3670 는 서열 번호 35와 서열 번호 36 또는 서열 번호 67의 염기 서열로 이루어진 이중 가닥 RNA로 구성되는 이중 가닥이 유효 성분으로 포함되는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서,상기 miR-4477a 는 서열 번호 43과 서열 번호 44 또는 서열 번호 68의 염기 서열로 이루어진 이중 가닥 RNA로 구성되는 이중 가닥이 유효 성분으로 포함되는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서,상기 miR-8078 는 서열 번호 65와 서열 번호 66 또는 서열 번호 69의 염기 서열로 이루어진 이중 가닥 RNA로 구성되는 이중 가닥이 유효 성분으로 포함되는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서,상기 miRNA는 암 세포의 자살 기전을 유도하여 암을 치료하는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서,상기 암은 폐암, 간암, 위암, 대장암, 췌장암, 담낭 및 담도암, 유방암, 백혈병, 식도암, 비호치킨 림프종, 갑상선암, 자궁경부암, 피부암의 원발성 암과 이로부터 기타 장기로 전이되어 유발되는 전이암 및 비정상적인 과다 세포 분열을 촉진하여 생성되는 종양성 세포 질환으로 구성되는 군으로부터 선택된 1종 이상의 암인 것을 특징으로 하는 약학 조성물.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 miRNA는 miRNA유도체인 것을 특징으로 하는 조성물.
- 제7항에 있어서, 상기 miRNA 유도체는 RNA 인산 뼈대 구조 (phosphate backbone structure)를 황 등의 다른 원소로 치환한 형태인 포스포로사이오에이트 (phosphorothiolate) 구조를 부분적으로 포함하는 형태; RNA 대신 DNA, PNA(petide nucleic acids) 및 LNA(locked nucleic acid) 분자로의 전체 또는 부분적으로 치환된 형태; 및 RNA 당의 2’수산화기를 메틸화, 메톡시화, 플르오르화 등의 기능성 구조로 치환한 형태로 구성된 군에서 선택되는 것을 특징으로 하는 조성물.
- 제7항에 있어서, 상기 miRNA 유도체는 pri-miRNA 또는 precursor miRNA의 miRNA 전구체 형태; 또는 플라스미드 형태의 miRNA 전구체로 구성되는 것을 특징으로 하는 조성물.
- 제9항에 있어서, 상기 miRNA 전구체는 RNA 인산 뼈대 구조 (phosphate backbone structure)를 황 등의 다른 원소로 치환한 형태인 포스포로사이오에이트 (phosphorothiolate) 구조를 부분적으로 포함하는 형태; RNA 대신 DNA, PNA(petide nucleic acids) 및 LNA(locked nucleic acid) 분자로의 전체 또는 부분적으로 치환된 형태; 및 RNA 당의 2’수산화기를 메틸화, 메톡시화, 플르오르화 등의 기능성 구조로 치환한 형태로 구성된 군에서 선택되는 것을 특징으로 하는 조성물.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017545217A JP6538183B2 (ja) | 2015-02-25 | 2016-02-25 | マイクロrnaを有効成分として含む癌治療用医薬組成物 |
US15/553,097 US10351849B2 (en) | 2015-02-25 | 2016-02-25 | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
CN201680018165.9A CN107454843B (zh) | 2015-02-25 | 2016-02-25 | 包含微小核糖核酸作为活性成分的用于治疗癌症的药物组合物 |
AU2016224201A AU2016224201B2 (en) | 2015-02-25 | 2016-02-25 | Pharmaceutical composition for treating cancer comprising microRNA as active ingredient |
RU2017132895A RU2686313C2 (ru) | 2015-02-25 | 2016-02-25 | Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента |
CA2977624A CA2977624C (en) | 2015-02-25 | 2016-02-25 | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
BR112017018318-8A BR112017018318A2 (ko) | 2015-02-25 | 2016-02-25 | A pharmaceutical composition for treating cancer comprising a micro RNA as an active ingredient |
EP16755885.7A EP3263135B1 (en) | 2015-02-25 | 2016-02-25 | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
US16/371,026 US10612026B2 (en) | 2015-02-25 | 2019-03-31 | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150026557 | 2015-02-25 | ||
KR10-2015-0026557 | 2015-02-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/553,097 A-371-Of-International US10351849B2 (en) | 2015-02-25 | 2016-02-25 | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
US16/371,026 Division US10612026B2 (en) | 2015-02-25 | 2019-03-31 | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2016137235A2 WO2016137235A2 (ko) | 2016-09-01 |
WO2016137235A3 WO2016137235A3 (ko) | 2016-10-20 |
WO2016137235A9 true WO2016137235A9 (ko) | 2016-11-24 |
Family
ID=56789628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/001828 WO2016137235A2 (ko) | 2015-02-25 | 2016-02-25 | 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 |
Country Status (10)
Country | Link |
---|---|
US (2) | US10351849B2 (ko) |
EP (1) | EP3263135B1 (ko) |
JP (1) | JP6538183B2 (ko) |
KR (2) | KR101862080B1 (ko) |
CN (2) | CN113633656A (ko) |
AU (1) | AU2016224201B2 (ko) |
BR (1) | BR112017018318A2 (ko) |
CA (2) | CA3134991A1 (ko) |
RU (1) | RU2686313C2 (ko) |
WO (1) | WO2016137235A2 (ko) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10619213B2 (en) | 2014-06-12 | 2020-04-14 | Toray Industries, Inc. | Prostate cancer detection kit or device, and detection method |
KR101861738B1 (ko) * | 2016-08-24 | 2018-05-29 | (주)바이오니아 | 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체 |
CN107058474B (zh) * | 2016-11-03 | 2020-09-01 | 中国人民解放军陆军军医大学 | 一种通过血浆microRNA-3591-3p诊断急性高山病的诊断试剂盒 |
KR20180075139A (ko) | 2016-12-26 | 2018-07-04 | 한국원자력의학원 | Ccnd3 또는 pak2 유전자의 발현을 저해하는 암을 치료하기 위한 약학적 조성물 |
US20210139895A1 (en) * | 2017-06-16 | 2021-05-13 | Prostemics Co., Ltd. | Pharmaceutical composition for preventing or treating cancer |
KR20200085801A (ko) * | 2017-11-09 | 2020-07-15 | 고쿠리츠다이가쿠호진 히로시마다이가쿠 | miRNA를 포함하는 암 치료용 의약 조성물 |
KR102138495B1 (ko) * | 2017-11-27 | 2020-07-28 | (주)프로스테믹스 | 이중 가닥의 올리고뉴클레오티드 및 그 제조 방법 |
KR102189991B1 (ko) * | 2017-11-27 | 2020-12-11 | (주)프로스테믹스 | miRNA를 포함하는 상처 치료 또는 피부 개선용 조성물 |
KR102189987B1 (ko) * | 2017-11-27 | 2020-12-11 | (주)프로스테믹스 | miRNA를 포함하는 탈모 방지 또는 발모 촉진용 조성물 |
KR102145176B1 (ko) * | 2017-11-27 | 2020-08-18 | (주)프로스테믹스 | 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
CN107881237B (zh) * | 2017-12-01 | 2020-11-20 | 唐山市人民医院 | 肺癌诊断标记物microRNA-4317及在药物和诊断试剂盒中的应用 |
KR102141124B1 (ko) * | 2018-01-30 | 2020-08-04 | (주)바이오니아 | 이중 가닥 miRNA를 포함하는 이중나선 올리고뉴클레오타이드 구조체 및 이의 용도 |
US10987428B2 (en) * | 2018-06-01 | 2021-04-27 | City Of Hope | Phosphorothioate-conjugated miRNAs and methods of using the same |
EP3835434A4 (en) * | 2018-08-10 | 2022-06-08 | Toray Industries, Inc. | PROSTATE CANCER DETECTION KIT, DEVICE AND METHOD |
KR102178919B1 (ko) * | 2018-11-26 | 2020-11-13 | 순천향대학교 산학협력단 | 당뇨병성 신증 진단을 위한 마이크로rna 바이오마커 및 이의 용도 |
KR102133205B1 (ko) | 2018-12-05 | 2020-07-13 | 충북대학교 산학협력단 | PNA-pHLIP 접합체를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
KR102418779B1 (ko) * | 2018-12-12 | 2022-07-08 | (주)프로스테믹스 | 신규한 miRNA 유사체 및 이의 용도 |
JPWO2020235671A1 (ko) * | 2019-05-23 | 2020-11-26 | ||
CN110184338B (zh) * | 2019-05-31 | 2023-04-07 | 南方医科大学第三附属医院(广东省骨科研究院) | 脑脊液外泌体miRNA在MMD诊断和治疗中的应用 |
EP3981473A4 (en) * | 2019-06-05 | 2023-06-28 | Cancerstem Tech Inc. | Therapeutic agent for cancer |
KR102085260B1 (ko) | 2019-06-19 | 2020-03-05 | 한국원자력의학원 | Ccnd3 또는 pak2 유전자의 발현을 저해하는 암을 치료하기 위한 약학적 조성물 |
CN110607368B (zh) * | 2019-09-19 | 2021-07-13 | 西安交通大学 | miRNA3926-1基因作为胰腺癌诊断和疗效标志物的应用 |
CN111467504A (zh) * | 2020-03-13 | 2020-07-31 | 南方医科大学 | miR-4469在制备抗结直肠癌药物中的应用 |
CN111349704B (zh) * | 2020-03-17 | 2020-11-24 | 河北医科大学第三医院 | 肝癌的诊断产品和治疗组合物 |
CN111466339A (zh) * | 2020-04-02 | 2020-07-31 | 华北理工大学 | miRNA-203a-3p在促进胰腺癌细胞增殖和迁移中的应用 |
CN111387143A (zh) * | 2020-04-02 | 2020-07-10 | 华北理工大学 | miRNA-203a-3p在开发抑制胰腺癌药物中的应用 |
US20230407401A1 (en) * | 2020-05-29 | 2023-12-21 | National Institute Of Immunology | Dna damage dependent microrna signature for cancers, methods and uses related thereto |
CN114058698B (zh) * | 2020-07-29 | 2023-08-15 | 四川大学华西医院 | 检测外泌体miR-6879-5p的试剂在制备甲状腺癌转移检测试剂盒中的用途 |
CN114058697B (zh) * | 2020-07-29 | 2023-08-18 | 四川大学华西医院 | 检测外泌体miR-6774-3p或miR-6776-5p的试剂的用途 |
WO2022087600A1 (en) * | 2020-10-20 | 2022-04-28 | Duquesne University Of The Holy Spirit | Micro rna interactions as therapeutic targets for covid-19 and other viral infections |
CN112094913B (zh) * | 2020-11-10 | 2021-03-30 | 广州市锐博生物科技有限公司 | 结直肠癌生物标志物及其用途 |
WO2022182188A1 (ko) * | 2021-02-25 | 2022-09-01 | (주)바이오니아 | 이중가닥 mirna를 유효성분으로 포함하는 모발의 회백색화 개선, 발모 촉진 및/또는 탈모의 예방 또는 개선용 조성물 |
CN113041255B (zh) * | 2021-04-13 | 2022-10-11 | 上海中医药大学 | 一种新发现miRNA–mRNA调控轴介导肺腺癌NCI-H1299细胞焦亡的方法 |
CN113981074A (zh) * | 2021-12-10 | 2022-01-28 | 石河子大学 | 一种与2型糖尿病相关的microRNA及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US15071A (en) * | 1856-06-10 | John h | ||
ATE523591T1 (de) * | 2005-04-12 | 2011-09-15 | Univ Bruxelles | Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlung |
CN101801419A (zh) | 2007-06-08 | 2010-08-11 | 米尔纳疗法公司 | 作为治疗干预的靶标的miR-34调控的基因和路径 |
KR101325186B1 (ko) * | 2008-01-23 | 2013-11-07 | (주)바이오니아 | 이중가닥 miRNA를 유효성분으로 포함하는 항암제 |
CA2721722C (en) | 2008-04-17 | 2015-12-08 | The Johns Hopkins University | On01910.na enhances chemotherapeutic agent activity in drug-resistant tumors |
US20120302626A1 (en) * | 2009-12-04 | 2012-11-29 | Sandeep Dave | Microrna and use thereof in identification of b cell malignancies |
AU2012223237A1 (en) | 2011-03-02 | 2013-05-02 | Groove Biopharma Corporation | Enhanced biodistribution of oligomers |
CN103505743A (zh) * | 2012-06-21 | 2014-01-15 | 北京命码生科科技有限公司 | 含功能性microRNA/siRNA的细胞微粒子及其应用 |
CA2886116C (en) | 2012-09-26 | 2022-06-07 | Mirrx Therapeutics | Oligomers with improved off-target profile |
JP6478916B2 (ja) * | 2012-11-16 | 2019-03-06 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 薬物耐性乳癌の予後判定および処置のための治療アジュバントおよびバイオマーカーとしてのmiRNA |
WO2014100252A1 (en) * | 2012-12-18 | 2014-06-26 | University Of Washington Through Its Center For Commercialization | Methods and compositions to modulate rna processing |
CN112094913B (zh) * | 2020-11-10 | 2021-03-30 | 广州市锐博生物科技有限公司 | 结直肠癌生物标志物及其用途 |
-
2016
- 2016-02-25 RU RU2017132895A patent/RU2686313C2/ru active
- 2016-02-25 AU AU2016224201A patent/AU2016224201B2/en not_active Ceased
- 2016-02-25 CA CA3134991A patent/CA3134991A1/en not_active Abandoned
- 2016-02-25 CA CA2977624A patent/CA2977624C/en active Active
- 2016-02-25 WO PCT/KR2016/001828 patent/WO2016137235A2/ko active Application Filing
- 2016-02-25 KR KR1020160022462A patent/KR101862080B1/ko active IP Right Grant
- 2016-02-25 CN CN202110786758.2A patent/CN113633656A/zh active Pending
- 2016-02-25 EP EP16755885.7A patent/EP3263135B1/en active Active
- 2016-02-25 JP JP2017545217A patent/JP6538183B2/ja not_active Expired - Fee Related
- 2016-02-25 US US15/553,097 patent/US10351849B2/en not_active Expired - Fee Related
- 2016-02-25 BR BR112017018318-8A patent/BR112017018318A2/ko not_active IP Right Cessation
- 2016-02-25 CN CN201680018165.9A patent/CN107454843B/zh not_active Expired - Fee Related
-
2018
- 2018-05-15 KR KR1020180055329A patent/KR101960067B1/ko active IP Right Grant
-
2019
- 2019-03-31 US US16/371,026 patent/US10612026B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20180054549A (ko) | 2018-05-24 |
JP2018507866A (ja) | 2018-03-22 |
KR101862080B1 (ko) | 2018-07-04 |
AU2016224201A1 (en) | 2017-09-21 |
JP6538183B2 (ja) | 2019-07-03 |
CA2977624C (en) | 2021-11-30 |
CN107454843B (zh) | 2021-07-30 |
CN113633656A (zh) | 2021-11-12 |
WO2016137235A2 (ko) | 2016-09-01 |
RU2017132895A3 (ko) | 2019-03-25 |
EP3263135A4 (en) | 2018-09-19 |
CA3134991A1 (en) | 2016-09-01 |
RU2017132895A (ru) | 2019-03-25 |
US10612026B2 (en) | 2020-04-07 |
BR112017018318A2 (ko) | 2018-07-10 |
KR20160103949A (ko) | 2016-09-02 |
CA2977624A1 (en) | 2016-09-01 |
CN107454843A (zh) | 2017-12-08 |
US20190218555A1 (en) | 2019-07-18 |
RU2686313C2 (ru) | 2019-04-25 |
US20180030440A1 (en) | 2018-02-01 |
WO2016137235A3 (ko) | 2016-10-20 |
US10351849B2 (en) | 2019-07-16 |
EP3263135A2 (en) | 2018-01-03 |
AU2016224201B2 (en) | 2018-07-05 |
KR101960067B1 (ko) | 2019-03-20 |
EP3263135B1 (en) | 2020-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016137235A2 (ko) | 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 | |
Wu et al. | Suppression of cell growth and invasion by miR-205 in breast cancer | |
Barsotti et al. | p53-Dependent induction of PVT1 and miR-1204 | |
Smorag et al. | MicroRNA signature in various cell types of mouse spermatogenesis: evidence for stage‐specifically expressed miRNA‐221,‐203 and‐34b‐5p mediated spermatogenesis regulation | |
Zhang et al. | MicroRNA-148a promotes myogenic differentiation by targeting the ROCK1 gene | |
Shi et al. | MiR-135a inhibits migration and invasion and regulates EMT-related marker genes by targeting KLF8 in lung cancer cells | |
Chen et al. | MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma | |
Yao et al. | MicroRNA-224 is involved in the regulation of mouse cumulus expansion by targeting Ptx3 | |
Liu et al. | Overexpressed miR-494 down-regulates PTEN gene expression in cells transformed by anti-benzo (a) pyrene-trans-7, 8-dihydrodiol-9, 10-epoxide | |
Cui et al. | miRNA-520b and miR-520e sensitize breast cancer cells to complement attack via directly targeting 3′ UTR of CD46 | |
Kesanakurti et al. | Suppression of tumor cell invasiveness and in vivo tumor growth by microRNA-874 in non-small cell lung cancer | |
Alteri et al. | Cyclin D1 is a major target of miR-206 in cell differentiation and transformation | |
Trakooljul et al. | Identification of target genes and pathways associated with chicken microRNA miR‐143 | |
US20230348911A1 (en) | Antisense oligonucleotides for modulation of long noncoding rnas | |
Sciamanna et al. | Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression | |
Attema et al. | Identification of an enhancer that increases miR-200b~ 200a~ 429 gene expression in breast cancer cells | |
Yang et al. | Downregulation of microRNA‑34b is responsible for the elevation of blood pressure in spontaneously hypertensive rats | |
Zhang et al. | Identification of miR-2400 gene as a novel regulator in skeletal muscle satellite cells proliferation by targeting MYOG gene | |
Bavelloni et al. | PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells | |
Kong et al. | MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein | |
Xie et al. | Inhibition of microRNA‑30a prevents puromycin aminonucleoside‑induced podocytic apoptosis by upregulating the glucocorticoid receptor α | |
WO2008068047A1 (en) | Micro rna targeting ets1 | |
EP2464730B1 (en) | miRNA COMPOUNDS FOR TREATMENT OF PROSTATE CARCINOMA | |
Du et al. | Discovery and functional characterization of microRNAs and their potential roles for gonadal development in spotted knifejaw, Oplegnathus punctatus | |
Lou et al. | MiR-2014-5p and miR-1231-5p regulate muscle growth of Larimichthys crocea by targeting MSTN gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16755885 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2977624 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2017545217 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017018318 Country of ref document: BR |
|
REEP | Request for entry into the european phase |
Ref document number: 2016755885 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016224201 Country of ref document: AU Date of ref document: 20160225 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017132895 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112017018318 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170825 |